Intellia Therapeutics (NTLA) Competitors $13.12 -1.01 (-7.15%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NTLA vs. VIVO, CLDX, SGMO, EDIT, CLLS, VKTX, LNTH, RNA, CRNX, and KRYSShould you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Meridian Bioscience (VIVO), Celldex Therapeutics (CLDX), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Cellectis (CLLS), Viking Therapeutics (VKTX), Lantheus (LNTH), Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX), and Krystal Biotech (KRYS). These companies are all part of the "medical" sector. Intellia Therapeutics vs. Meridian Bioscience Celldex Therapeutics Sangamo Therapeutics Editas Medicine Cellectis Viking Therapeutics Lantheus Avidity Biosciences Crinetics Pharmaceuticals Krystal Biotech Intellia Therapeutics (NASDAQ:NTLA) and Meridian Bioscience (NASDAQ:VIVO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment. Do analysts rate NTLA or VIVO? Intellia Therapeutics currently has a consensus target price of $54.94, suggesting a potential upside of 318.73%. Given Intellia Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Intellia Therapeutics is more favorable than Meridian Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 0 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.72Meridian Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of NTLA or VIVO? 88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 89.7% of Meridian Bioscience shares are held by institutional investors. 3.2% of Intellia Therapeutics shares are held by insiders. Comparatively, 2.3% of Meridian Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, NTLA or VIVO? Intellia Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Meridian Bioscience has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Does the media refer more to NTLA or VIVO? In the previous week, Intellia Therapeutics had 25 more articles in the media than Meridian Bioscience. MarketBeat recorded 25 mentions for Intellia Therapeutics and 0 mentions for Meridian Bioscience. Intellia Therapeutics' average media sentiment score of 0.51 beat Meridian Bioscience's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Intellia Therapeutics Positive Meridian Bioscience Neutral Is NTLA or VIVO more profitable? Meridian Bioscience has a net margin of 12.70% compared to Intellia Therapeutics' net margin of 0.00%. Meridian Bioscience's return on equity of 16.74% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia TherapeuticsN/A -49.34% -40.27% Meridian Bioscience 12.70%16.74%13.09% Which has preferable earnings & valuation, NTLA or VIVO? Meridian Bioscience has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Meridian Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$36.28M36.83-$481.19M-$5.44-2.41Meridian Bioscience$333.02M4.49$42.46M$0.9735.02 Does the MarketBeat Community believe in NTLA or VIVO? Intellia Therapeutics received 119 more outperform votes than Meridian Bioscience when rated by MarketBeat users. Likewise, 69.27% of users gave Intellia Therapeutics an outperform vote while only 48.69% of users gave Meridian Bioscience an outperform vote. CompanyUnderperformOutperformIntellia TherapeuticsOutperform Votes43569.27% Underperform Votes19330.73% Meridian BioscienceOutperform Votes31648.69% Underperform Votes33351.31% SummaryIntellia Therapeutics beats Meridian Bioscience on 11 of the 19 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTLA vs. The Competition Export to ExcelMetricIntellia TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.44B$2.20B$5.06B$8.89BDividend YieldN/A0.75%4.97%4.06%P/E Ratio-2.412.6189.0213.30Price / Sales36.8341.431,207.2881.01Price / CashN/A14.8239.1736.03Price / Book1.393.116.085.74Net Income-$481.19M$29.98M$119.07M$225.93M7 Day Performance-13.23%-1.26%-1.84%-1.32%1 Month Performance-36.53%-9.92%-3.65%0.60%1 Year Performance-53.90%-14.62%31.62%26.23% Intellia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTLAIntellia Therapeutics4.5389 of 5 stars$13.12-7.1%$54.94+318.7%-56.7%$1.44B$36.28M-2.41600Analyst ForecastVIVOMeridian Bioscience1.0351 of 5 stars$33.97flatN/AN/A$1.50B$333.02M35.02702Analyst ForecastCLDXCelldex Therapeutics2.8782 of 5 stars$26.40+5.7%$62.25+135.8%-3.0%$1.66B$6.88M0.00160Analyst ForecastNews CoverageSGMOSangamo Therapeutics2.1859 of 5 stars$1.95-0.5%$7.00+259.0%+369.9%$408.95M$176.23M0.00480Analyst RevisionGap UpEDITEditas Medicine4.7809 of 5 stars$2.41-2.8%$9.08+276.9%-77.8%$204.72M$78.12M0.00230Short Interest ↓CLLSCellectis2.4726 of 5 stars$1.91-2.6%$7.00+266.5%-38.4%$108.94M$9.19M0.00290Analyst ForecastVKTXViking Therapeutics4.7696 of 5 stars$51.53+0.0%$109.80+113.1%+337.8%$5.74BN/A0.0020Analyst ForecastGap UpLNTHLantheus4.5262 of 5 stars$86.45+8.8%$122.50+41.7%+25.1%$5.52B$1.30B14.38834Positive NewsGap UpRNAAvidity Biosciences2.3883 of 5 stars$43.65+0.9%$63.22+44.8%+631.2%$5.16B$9.56M0.00190Insider TradeAnalyst RevisionCRNXCrinetics Pharmaceuticals3.5524 of 5 stars$56.07+1.6%$70.18+25.2%+85.5%$5.12B$4.01M0.00210Analyst RevisionKRYSKrystal Biotech4.8348 of 5 stars$178.10+0.1%$202.29+13.6%+70.0%$5.12B$50.70M100.62229Positive News Related Companies and Tools Related Companies Meridian Bioscience Alternatives Celldex Therapeutics Alternatives Sangamo Therapeutics Alternatives Editas Medicine Alternatives Cellectis Alternatives Viking Therapeutics Alternatives Lantheus Alternatives Avidity Biosciences Alternatives Crinetics Pharmaceuticals Alternatives Krystal Biotech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NTLA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
